Before you can access ASH's online program, you must agree to the following:
Last updated January 16, 2009. Please note that this site represents the latest program changes
and differs from the print version in some details.

604.O4.8 New Targeted Drugs (pre-clinical)

Tuesday, December 9, 2008: 7:00 AM-9:00 AM
Yerba Buena Ballroom Salon 8 (San Francisco Marriott)
Moderators:
Thomas Fischer, MD and Douglas D. Ross, MD, PhD
7:00 AM
Effects of CYT387, a Potent Novel JAK2 Inhibitor on JAK2-V617F Induced MPD

Thomas G.P. Bumm1*, Jeffrey W Tyner, PhD2*, Jutta Deininger2*, Marc Loriaux2*, Jonathan VanDyke2*, Brian J. Druker2, Christopher J Burns3*, Emmanuelle Fantino3* and Michael W.N. Deininger, MD2

1Center for Hematologic Malignancies, Oregon Health & Science University, Portland, OR
2Oregon Health & Science University Cancer Institute, Portland, OR
3Cytopia Research Pty Ltd, Melbourne, Victoria, Australia, Richmond, Australia

7:15 AM
Small Molecule XIAP Inhibitors Cooperate with TRAIL to Trigger Apoptosis in Childhood Acute Leukemia Cells and Overcome Bcl-2-Mediated Resistance

Melanie Fakler1*, Sandra Löder1*, Meike Vogler1*, Katja Schneider2*, Irmela Jeremias2*, Klaus-Michael Debatin, MD3 and Simone Fulda1*

1Children's Hospital, Ulm University, Ulm, Germany
2Gene Vectors, GSF – Research Center for Environment and Health, Munich, Germany
3Department of Pediatrics and Adolescent Medicine, University of Ulm, Ulm, Germany

7:30 AM
Oral Small Molecule Inhibitor of VLA-4 Overcomes Adhesion Mediated Chemotherapy Resistance of Acute Myeloid Leukemia (AML) Blasts in Vitro, without Impairment of Normal Blood Cell Recovery When Combined with Chemotherapy in Vivo

Pamela S. Becker, MD, PhD1, Frederick R. Appelbaum, MD2, Sylvia Chien3*, Xin Zhao, MD3*, Halvard Bonig, MD1*, Ryuta Mukasa, PhD4* and Thalia Papayannopoulou, MD3

1Division of Hematology, University of Washington, Seattle, WA
2Fred Hutchinson Cancer Research Center, University of Washington School of Medicine, Seattle, WA
3University of Washington, Seattle, WA
4R & D Dvision, Daiichi Sankyo Company, Ltd, Tokyo, Japan

7:45 AM
AC220 Is a Uniquely Potent and Selective Second-Generation FLT3 Inhibitor

Patrick P Zarrinkar, PhD*, Robert C Armstrong, Ph.D.*, Ruwanthi N Gunawardane, Ph.D.*, Joyce James, PhD*, Mazen W Karaman, Ph.D.* and Shripad S Bhagwat, PhD*

Ambit Biosciences, San Diego, CA

8:00 AM
Development of Mek inhibition (MEK-I)-Based Therapeutic Strategies in Acute Myeloid Leukemia (AML)

Michele Milella, MD1, Maria Rosaria Ricciardi2*, Paola Bergamo, MS1*, Maria Cristina Scerpa, PhD3*, Jacopo Gervasoni, MS4*, Maria Teresa Petrucci, MD5, Sabina Chiaretti, MD6*, Simona Tavolaro, MS3*, Ludovica Ciuffreda, PhD1*, Samantha Decandia2*, Francesco Libotte2*, Stephen Lee Abrams7*, Linda S Steelman, BS., MS7*, Marina Konopleva, MD, PhD8, Francesco Cognetti, MD1*, Robert Foa9, Michael Andreeff, MD, PhD10, James McCubrey, PhD11 and Agostino Tafuri12

1Medical Oncology A, Regina Elena National Cancer Institute, Rome, Italy
2Division of Hematology, Department of Cellular Biotechnologies and Hematology, University La Sapienza, Roma, Italy
3Division of Hematology-Dept. of Cellular Biotechnologies and Hematology, University of Rome "La Sapienza", Rome, Italy
4Division of Hematology-Dept. of Cellular Biotechnologies and Hematology, University of Rome, Rome, Italy
5Hematology, University La Sapienza, Rome, Italy
6MILE Study Group, on Behalf of European LeukemiaNet (ELN, WP13), Munich, Germany
7Micro & Immun, East Carolina University, Greenville, NC
8Leukemia, The University of Texas M.D. Anderson Cancer Center, Houston, TX
9Dept. of Cellular Biotechnologies & Hematology, University 'Sapienza', Rome, Italy
10Stem Cell Transplantation & Cellular Therapy, The University of Texas M.D. Anderson Cancer Center, Houston, TX
11School of Medicine, East Carolina University, Greenville, NC
12Division of Hematology-Dept. of Cellular Biotechnologies and Hematology, University La Sapienza, Roma, Italy

8:15 AM
Effects of the Mcl-1/Bcl-2 Inhibitor GX015-070 (Obatoclax®) on Growth and Viability of Canine and Human Neoplastic Mast Cells

Barbara Peter, MVM1*, Karl J. Aichberger, MD1*, Karoline V. Gleixner, MD1*, Veronika Ferenc, MD1*, Alexander Gruze2*, Winfried F. Pickl, MD2*, Michael Willmann, DVM3* and Peter Valent, MD1

1Department of Internal Medicine I, Division of Hematology & Hemostaseology, Medical University of Vienna, Vienna, Austria
2Institute of Immunology, Medical University of Vienna, Vienna, Austria
3Department of Companion Animals and Horses, Clinic for Internal Medicine and Infectious Diseases, University of Veterinary Medicine Vienna, Vienna, Austria

8:30 AM
A Stapled BIM BH3 Helix Overcomes the MCL-1-Mediated Apoptotic Blockade of Refractory Hematologic Cancers

James L. LaBelle, MD, PhD, Chelsea E. Lawrence*, Gregory H. Bird, Ph.D.* and Loren D. Walensky, M.D., Ph.D.

Pediatric Oncology and the Program in Cancer Chemical Biology, Dana-Farber Cancer Institute, Children's Hospital Boston, Harvard Medical School, Boston, MA

8:45 AM
Strategies for Therapeutic Peptide Delivery by Mesenchymal Stem Cells

Xian-Yang Zhang, PhD1*, Lisa To, BA2*, Jakob Reiser, PhD3*, Charles S. Hemenway, MD, PhD4, Michel W Sadelain, MD, PhD5 and Vincent F. La Russa, PhD6

1Genetics, Louisiana State University, New Orleans, LA
2School of Medicine, Louisiana State University, New Orleans, LA
3FDA, Bethesda, MD
4Loyola University Medical Center, Maywood, IL
5Memorial Sloan-Kettering Cancer Center, New York, NY
6Cytotherapy Laboratory, Memorial Sloan Kettering Cancer Center, New York, NY

*signifies non-member of ASH